Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5039025 | 0.77 | PIK3CD (0.47) | PIK3CDHRH3KDM4EALDH1A1TDP1 | |
| SCHEMBL4508583 | 0.77 | PIK3CD (0.47) | PIK3CDHRH3KDM4EALDH1A1TDP1 | |
| SCHEMBL20801730 | 0.76 | PIK3CD (0.39) | PIK3CDHRH3KDM4EALDH1A1TDP1 | |
| SCHEMBL15332381 | 0.76 | PIK3CD (0.42) | PIK3CDHRH3KDM4EALDH1A1TDP1 | |
| SCHEMBL26370219 | 0.74 | PIK3CD (0.38) | PIK3CDHRH3KDM4EALDH1A1TDP1 | |
| SCHEMBL22733424 | 0.74 | HRH3 (0.33) | HRH3ALDH1A1CYP2D6 | |
| SCHEMBL27358276 | 0.73 | PIK3CD (0.37) | PIK3CDHRH3KDM4EALDH1A1TDP1 | |
| SCHEMBL13312886 | 0.71 | PIK3CD (0.55) | PIK3CDHRH3KDM4EALDH1A1TDP1 | |
| SCHEMBL3419549 | 0.71 | PIK3CD (0.41) | PIK3CDHRH3KDM4EALDH1A1TDP1 | |
| SCHEMBL21311463 | 0.70 | PIK3CD (0.45) | PIK3CDHRH3KDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885HRH3 3631/4885KDM4E 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.